In our January issue:
FEATURES
Cover Story
Pharm Exec’s 2015 Industry Outlook
Julian Upton, Casey McDonald
Following a year where a phenomenal cure was met by pricing outrage, the march of new products, including vaccines for malaria and dengue fever, and promising immunotherapy cancer combos will continue in 2015. As pharma and tech jell, how will the industry live up to its value supposition while pricing and profiting in the developed and developing worlds? |
Regulatory
Politics & Prices Dominate 2015 Agenda
Jill Wechsler
The coming months will be challenging for biopharma companies, as scrutiny continues to intensify over prices of new drugs and biotech therapies, while demand escalates for more safe and effective treatments for deadly diseases at home and abroad. Patient alliances can help pharma explain the important trade-offs in risks and benefits, writes Jill Wechsler. |
Executive Interview
Pascale Witz and Sanofi’s Big Bet on Integrated Patient Care
Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare. |
From the Editor
Five Years, Five Key Performance Measures: Keeping Score of Pharma's Progress
William Looney
Pharm Exec Editor-in-Chief William Looney writes: "Five years ago, I offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance. Here, in no assigned order, is our update on the five criteria and whether the industry deserves a check or a minus in moving forward on each."
|
 |
ALSO IN THIS ISSUE
Supply Chain Analytics: Pharma’s Next Big Bet
Srihari Rangarajan, Jacob Snapp
Why supply chain analytics is the strategic differentiator for pharma companies to excel in the face of adversity, and will ultimately help these companies become world-class drug or medical device suppliers.
The Hidden Forces of Behavioral Economics
Daryl Travis
Patients and clinicians decide to use or not to use products and brands for reasons that are not always rational. In fact, an overwhelming body of evidence confirms patients and physicians alike often behave, dare we say, "irrationally". |
| WEBCASTS |
| Avoid the Last Minute Rush — Planning Ahead for Successful Global Market Access
|
| Market Access for Orphan Drugs in China |
Engineer Your Business to Win in the Mobile Selling Moment
|
